ArturoLoaiza-BonillaMDMSEd, FACP

Oncology • Allentown, PA

Cancer Genetics/Cancer Risk Assessment, Gastrointestinal Cancer, Hematologic Oncology

Medical Director of Oncology Research

Join to view full profile

Dr. Loaiza-Bonilla is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Loaiza-Bonilla's full profile

Already have an account?

Office
St. Luke's Cancer Care Associates Surgical Oncology - Allentown
240 Cetronia Rd, Ste 225
Allentown, PA 18104
Phone+1 484-503-4673

Summary

Dr. Arturo Loaiza-Bonilla is Systemwide Chief of Hematology and Oncology at St. Luke's University Health Network & Associate Professor of Medicine at the Lewis Katz SOM at Temple University

He also speaks multiple languages, including French, Spanish, Japanese. He specializes in cancer genetics, gastrointestinal cancer, experienced in immunotherapy, clinical research, AI, digital & global health.

Education & Training

University of PennsylvaniaMSEd, Medical Education, 2014 - 2016
University of Miami/Jackson Health SystemFellowship, Hematology and Medical Oncology, 2010 - 2013
Johns Hopkins University School of MedicinePost-Doctoral Fellowship, 2007 - 2010
MedStar Health/Harbor HospitalResidency, Internal Medicine, 2007 - 2010
National University of ColombiaClass of 2004

Certifications & Licensure

NJ State Medical License 2022 - 2025
PA State Medical License 2013 - 2024
GA State Medical License 2021 - 2022
FL State Medical License Active through 2014
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Top 40 Under 40 Philadelphia Business Journal, 2018
Castle Connolly Top Doctor Recognition Castle Connolly, 2018
President Elect Pennsylvania Society of Oncology and Hematology, 2018
Fellowship American College of Physicians, 2015
Leadership Academy American Society of Hematology, 2012
Leadership Award American Medical Association Foundation, 2010
Summa Cum Laude honor National University of Colombia, 2004
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Join now to see all

Clinical Trials

A Study of TAS-120 in Patients With Advanced Solid Tumors Start of enrollment: 2014 Jul 21
Completed
Phase 1, Phase 2
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer Start of enrollment: 2016 Mar 14
Recruiting
Phase 2
Determine Function of Antroquinonol in Combination With SOC in First Line Metastatic Pancreatic Cancer Start of enrollment: 2017 Dec 01
Active, not recruiting
Phase 1, Phase 2
PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies Start of enrollment: 2018 Jan 24
Completed
Phase 2
Phase 3 Study of Tislelizumab Versus Sorafenib in Participants With Unresectable HCC Start of enrollment: 2017 Dec 28
Completed
Phase 3
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry Start of enrollment: 2018 Jan 01
Recruiting
A Phase 3 Efficacy, Safety and Tolerability Study of Zolbetuximab (Experimental Drug) Plus mFOLFOX6 Chemotherapy Compared to Placebo Plus mFOLFOX6 as Treatment for Gastric and Gastroesophageal Junction (GEJ) Cancer Start of enrollment: 2018 Jun 21
Active, not recruiting
Phase 3
Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811) Start of enrollment: 2018 Oct 05
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

Achieving white blood cell equity: are the safety profiles of biosimilar and reference pegfilgrastims comparable?
Arturo Loaiza-Bonilla, Ray D Page
Future Oncology. 2024-01-01
7 citations
Clinical and treatment characteristics of patients treated with the first therapeutic oncology biosimilars bevacizumab-awwb and trastuzumab-anns in the US:
Ran Jin, Reshma Mahtani, Neil A. Accortt, Tatiana Lawrence, Darcie Sandschafer
Therapeutic Advances in Medical Oncology. 2021-09-01
1 citations
Concurrent Nab-paclitaxel and Radiotherapy: Novel Radiosensitization for Borderline Resectable or Unresectable Pancreatic Cancer.
William Tristram Arscott, Kevin T. Nead, Adham S. Bear, Sriram Venigalla, Jacob E. Shabason
American Journal of Clinical Oncology. 2021-09-01

Press Mentions

Massive Bio and NeoGenomics Announce Collaboration to Accelerate Oncology Drug Discovery and Improve Patient CareMarch 22nd, 2023
Clinical Trials Demystified by Massive Bio’s Chief Medical OfficerFebruary 28th, 2023
Massive Bio Announces Plans to Expand AI Use in Oncology, from Clinical Trial Matching to Drug Matching and BeyondJanuary 5th, 2023
Join now to see all

Professional Memberships

American Medical Association - AMA
Member
American College of Physicians - ACP
Fellow
American Society of Clinical Oncology - ASCO
Member
American Society of Hematology - ASH
Member

Other Languages

French, Spanish, Japanese

External Links

LinkedInhttps://www.linkedin.com/in/arturoloaizabonillla
CTCA websitehttps://www.cancercenter.com/eastern/doctors-and-clinicians/arturo-loaiza-bonilla/